Bone sarcoma during pregnancy: an example of personalized multidisciplinary care

Figures & data

Figure 1. MRI and PET scan showing the tumor before treatment (left) and after two courses of chemotherapy (right).

Table 1. Reported single cases of bone sarcoma during pregnancy.

Study	Age	Term	Tumor	Metastatic disease	Chemotherapy before delivery	Surgery before delivery	Delivery	Outcome maternal	Outcome fetal
Correa 2012	26 yr	33 wks	OS scapula	Y	N	N	CS, 33 wks	†2 d after delivery	Unknown
Schur 2012	27 yr	18 wks	ES pelvis	N	Y VIDE	N	VD, unknown term	NED 11 months FU	†Intra-uterine after 1^st course
Quaye 2010	33 yr	33 wks	OS femur	N	N	N	CS, unknown term	NED Unknown FU	Healthy at birth
Kanazawa 2009	38 yr	37 wks	OS lower jaw	N	N	N	CS, 38 wks	NED 3 years FU	Unknown
Nakajima 2004	17 yr	22 wks	ES thigh, extra-skeletal	N	Y DI	N	CS, 32 wks	†7 months after delivery	Delivery: SGA Healthy at 8 months
Merimsky 1999	21 yr	6th month	ES pelvis	N	Y DI	N	CS, 36 wks	NED 24 months FU	Healthy at 24 months
Haerr 1985	21 yr	25 wks	ES pelvis	N	Y T6 protocol without MTX	N	CS, 34 wks	NED 4 years FU	Healthy, low birth weight, mild RDS 2 d. Healthy at 4 years
Lysyj 1963 [13]	21 yr	32 wks	ES pelvis	Y	N	N	CS, 36 wks	†4 months after delivery	Unknown

yr: years; wks: weeks; OS: osteosarcoma; ES: Ewing sarcoma; Y: yes; N: no; MTX: Methotrexate; CS: cesarean section; VD: vaginal delivery; NED: no evidence of disease; FU: follow-up; SGA: small for gestational age; RDS: respiratory distress syndrome; VIDE: vincristin, ifosfamide, doxorubicin, etoposide; DI: doxorubicin, ifosfamide; T6 protocol: Dactinomycin, Cyclophosphamide, Bleomycin, Vincristine and Doxorubicin. †: deceased.